Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery

被引:2
|
作者
Xiong, Anning [1 ]
Li, Changhui [1 ]
Xu, Jianlin [1 ]
Yang, Xiaohua [1 ]
Nie, Wei [1 ]
Zhong, Hua [1 ]
Chu, Tianqing [1 ]
Zhang, Wei [1 ]
Zhong, Runbo [1 ]
Pan, Feng [1 ]
Shen, Yinchen [1 ]
Lou, Yuqing [1 ]
Zhang, Bo [1 ]
Han, Baohui [1 ]
Zhang, Xueyan [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, 241 Huaihai West Rd, Shanghai 200030, Peoples R China
关键词
Histologic subtype; Distant metastasis; Non-Small cell lung cancer; RESPIRATORY SOCIETY CLASSIFICATION; INTERNATIONAL-ASSOCIATION; CANCER; IMPACT; SURVIVAL; FEATURES; DISEASE; PROGNOSIS; RISK;
D O I
10.1016/j.lungcan.2021.02.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study aimed to explore the prognostic significance of solid pattern for bone metastases (BM) in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma patients after surgery. A total of 237 stage I-III lung adenocarcinoma patients with EGFR mutation were analyzed after procedure. The patients were divided into four groups: the solid-present patients with BM, the solid-absent patients with BM, the solid-present patients without BM and the solid-absent patients without BM. The bone disease-free survival (bDFS), systemic disease-free survival (DFS) and overall survival (OS) were assessed. The results revealed that the patients with solid pattern had shorter DFS (15 months vs. 19 months; P < 0.001) and OS (47 months vs. 77 months; P = 0.001). Moreover, bDFS of solid-present patients was significantly shorter than solid-absent patients (27 months vs. 14 months; P < 0.001). In addition, patients with solid component had worsened bDFS, no matter with BM as first-site development (12.5 months vs. 16.5 months; P = 0.016) or nonfirst-site development (16.5 months vs. 45.5 months; P < 0.001). These findings suggested that solid pattern predicted worse DFS and OS and also showed shortened interval between surgery and BM.
引用
收藏
页码:124 / 130
页数:7
相关论文
共 50 条
  • [21] Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma
    Gao, Song
    Stein, Seth
    Petre, Elena N.
    Shady, Waleed
    Durack, Jeremy C.
    Ridge, Carole
    Adusumilli, Prasad
    Rekhtman, Natasha
    Solomon, Stephen B.
    Ziv, Etay
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2018, 41 (02) : 253 - 259
  • [22] Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
    Ying Yuan
    Chunwen Tan
    Modan Li
    Hong Shen
    Xuefeng Fang
    Yinghong Hu
    Shenglin Ma
    World Journal of Surgical Oncology, 10
  • [23] Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
    Yuan, Ying
    Tan, Chunwen
    Li, Modan
    Shen, Hong
    Fang, Xuefeng
    Hu, Yinghong
    Ma, Shenglin
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2012, 10
  • [24] Sensitive Detection of EGFR Mutations in Cerebrospinal Fluid from Lung Adenocarcinoma Patients with Brain Metastases
    Yang, Haihong
    Cai, Linbo
    Zhang, Yalei
    Tan, Hongyu
    Deng, Qiuhua
    Zhao, Meiling
    Xu, Xin
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (05) : 558 - 563
  • [25] Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?
    Lim, Chor-Kuan
    Wei, Yu-Feng
    Tsai, Mao-Song
    Chen, Kuan-Yu
    Shih, Jin-Yuan
    Yu, Chong-Jen
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : 32 - 40
  • [26] Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database
    Kobayashi, Keigo
    Soejima, Kenzo
    Fukunaga, Koichi
    Shintani, Yasushi
    Sekine, Ikuo
    Shukuya, Takehito
    Takayama, Koichi
    Inoue, Akira
    Okamoto, Isamu
    Kiura, Katsuyuki
    Takahashi, Kazuhisa
    Yamamoto, Nobuyuki
    Takiguchi, Yuichi
    Miyaoka, Etsuo
    Okumura, Meinoshin
    Yoshino, Ichiro
    LUNG CANCER, 2020, 146 : 236 - 243
  • [27] Small cell conversion complicated with hypertrophic pulmonary osteoarthropathy after targeted therapy for advanced EGFR-mutated lung adenocarcinoma: A case report
    Zhang, Sijia
    Chen, Leichong
    Zhu, Kuikui
    Meng, Rui
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2024, 67 (01) : 217 - 222
  • [28] Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma
    Uehara, Yuji
    Izumi, Hiroki
    Taki, Tetsuro
    Sakai, Tetsuya
    Udagawa, Hibiki
    Sugiyama, Eri
    Umemura, Shigeki
    Zenke, Yoshitaka
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Kubota, Shoko
    Aokage, Keiju
    Sakamoto, Naoya
    Sakashita, Shingo
    Kojima, Motohiro
    Nagamine, Michiko
    Hosomi, Yukio
    Tsuboi, Masahiro
    Goto, Koichi
    Ishii, Genichiro
    JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (03):
  • [29] Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs
    Qi Gui
    Jiangang Liu
    Dapeng Li
    Chengcheng Xu
    World Journal of Surgical Oncology, 15
  • [30] Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs
    Gui, Qi
    Liu, Jiangang
    Li, Dapeng
    Xu, Chengcheng
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2017, 15